11:10 AM EST, 02/21/2025 (MT Newswires) -- Estrella Immunopharma ( ESLA ) said Friday it has completed the first dose group in its ongoing phase I/II clinical trial evaluating EB103 in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Based on preliminary data, no dose-limiting toxicities or serious adverse events related to treatment were observed in the group, with tumor response noted in all patients in the first month, the company said.

After reviewing safety and efficacy data, the Data and Safety Monitoring Board has approved the initiation of a higher dose group, the company added.

The company's shares were up 4% in recent trading.

Price: 1.55, Change: +0.06, Percent Change: +4.03